Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service colonoscopy & upper endoscopy cases in New Jersey: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 1% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 607 | 129,771 | 33% |
| 2020 | 568 | 96,558 | 36% |
| 2021 | 573 | 117,856 | 39% |
| 2022 | 576 | 117,366 | 41% |
| 2023 | 576 | 121,231 | 43% |
| 2024 | 581 | 123,352 | 45% |
| 2025 from claims | – | 126,767 116,337–134,119 | 46% |
| 2026 forecast | – | 129,241 113,712–149,139 | 46% |
| 2027 forecast | – | 131,470 112,392–156,672 | 47% |
| 2028 forecast | – | 133,729 111,584–163,747 | 47% |
| 2029 forecast | – | 136,017 111,094–170,578 | 47% |
| 2030 forecast | – | 138,335 110,825–177,275 | 48% |
Diagnostic and therapeutic colonoscopy and EGD; identifies every active endoscopist. Professional codes (what the surgeon bills): CPT 45378, 45380, 45385, 45390, 43239, 43235, 43251.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 6% of the cases CMS names in New Jersey; 307 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 10% inpatient hospital, 31% hospital outpatient, 58% surgery center, 2% office.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center | Office |
|---|---|---|---|---|
| 2026 · ~129,200 | ~12,500 | ~40,500 | ~74,000 | ~2,300 |
| 2027 · ~131,500 | ~12,500 | ~41,600 | ~75,000 | ~2,300 |
| 2028 · ~133,700 | ~12,600 | ~42,500 | ~76,200 | ~2,300 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 32% (31% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 1,378 | 235,327−1.7%/yr | −1.7%/yr | 134.5 | 54% | 246,900 in 2030+0.8%/yr |
| Pennsylvania | 915 | 164,346−1.8%/yr | −1.8%/yr | 125.5 | 44% | 166,800 in 2030+0.2%/yr |
| Massachusetts | 512 | 113,822−0.9%/yr | −0.9%/yr | 123.6 | 22% | 128,100 in 2030+2%/yr |
| Connecticut | 245 | 39,442−4.5%/yr | −4.5%/yr | 124.1 | 50% | 44,000 in 2030+1.8%/yr |
| New Hampshire | 83 | 23,743−2%/yr | −2%/yr | 107.6 | 28% | 31,200 in 2030+4.7%/yr |
| Maine | 77 | 12,348−6.2%/yr | −6.2%/yr | 81.7 | 16% | 12,100 in 2030−0.4%/yr |
| Rhode Island | 62 | 12,155−5.7%/yr | −5.7%/yr | 139.8 | 57% | 12,900 in 2030+1%/yr |
| Vermont | 43 | 7,313−0.6%/yr | −0.6%/yr | 65.8 | 14% | 14,500 in 2030+12%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| ERCP & endoscopic ultrasound | 46 | 3,131−1%/yr | −1%/yr | 3.00.8× | 3% | 3,440 in 2030+1.6%/yr |
| Bronchoscopy & lung nodule | 36 | 2,104+9.9%/yr | +9.9%/yr | 2.00.7× | 0% | 4,020 in 2030+11%/yr |
Colonoscopy & upper endoscopy in every state, and its device makers · Every procedure market in New Jersey · Every state · Compare with New York
Capsovision leads with 35% of company spending on these surgeons in 2025, −14 pts on 2024.
In 2025, 19 companies reported engagement with New Jersey’s surgeons worth $101K in consulting, speaking, meals and travel tied to these products, about $173 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 13 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.